How does ixazomib work?

Ixazomib is an anti-tumor drug that is used in combination with lenalidomide and dexamethasone and is suitable for patients with multiple myeloma who have received at least one previous treatment.

Ixazomibis a reversible proteasome inhibitor that preferentially binds to and inhibits the chymotrypsin-like activity of the 20Sproteasomeβ5 subunit. IxazomibInduces apoptosis in multiple myeloma cells in vitro. Ixazomibdemonstrated in vitro cytotoxicity against myeloma cells derived from patients who had relapsed after prior treatment with multiple therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomiband lenalidomide shows synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse xenograft model of multiple myeloma.

After oral administration, the median time to reach peak plasma concentrations of ixazomib is 1 hour. Based on population pharmacokinetic analysis, the mean absolute oral bioavailability is 58%. The AUC of ixazomib increased in a dose-proportional manner over the dose range of 0.2 to 10.6 mg. A food-effect study in patients taking a single dose of 4 mg of ixazomib showed that a high-fat meal decreased the AUC of ixazomib by 28%, C. Maximum69%. Ixazomib is 99% bound to plasma proteins and distributed into red blood cells with a plasma ratio of 10. The steady-state volume dispensed is 543 L. According to population pharmacokinetic analysis, the systemic clearance rate is approximately 1.9L/ hours, and the inter-individual difference is 44%. The terminal half-life (t1/2) is 9.5 days. After weekly oral dosing, the accumulation ratio was determined to be 2 times. Retail price of Lucius Pharmaceuticals in Laos4mg*3tablets900About 1 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.